Volume 76, Issue 2 , Pages 485-489, 1 February 2010
Effects of Bladder Distension on Organs at Risk in 3D Image-Based Planning of Intracavitary Brachytherapy for Cervical Cancer
Purpose
To investigate the effects of bladder distension on organs at risk (OARs) in the image-based planning of intracavitary brachytherapy for cervical cancer.
Methods and Materials
Thirteen patients with cancer of the cervix were treated with high-dose radiation brachytherapy (800 cGy/fraction for 3 fractions). For the three-dimensional (3D) analysis, pelvic CT scans were obtained from patients with indwelling catheters in place (defined as empty bladder) and from patients who received 180-cc injections of sterile water in their bladders (defined as full bladder). To compare the International Commission on Radiation Units and Measurements (ICRU) point doses with 3D-volume doses, the volume dose was defined by using two different criteria, D2cc (the minimum dose value in a 2.0-cm3 volume receiving the highest dose) and D50% (the dose received by 50% of the volume of the OAR) for OARs.
Results
The bladder D2cc was located more cranially in the bladder base and was distributed in multiple spots in 46% of patients. The rectal D2cc was located in the area of the ICRU point as a single “hot spot.” For patients with a full bladder, the mean bladder D2cc increased from 634 to 799 cGy (28.8%, p = 0.002). However, the bowel D2cc decreased from 475 to 261 cGy (45.0%, p < 0.001). There were no substantial differences in rectal and sigmoid D2cc values. However, the mean D50% values of both the bladder and the bowel decreased from 108 to 80 cGy (23.7%, p < 0.001) and from 282 to 221 cGy (19.7%, p = 0.004) with a full bladder, respectively.
Conclusions
An increase in bladder volume resulted in a significant reduction in bowel D2cc values at the expense of an increase in bladder D2cc values. Treatment with a distended bladder is preferable to protect the bowel.
Cervical cancer, Intracavitary brachytherapy, 3D Treatment planning, Bladder distension, High-dose rate
To access this article, please choose from the options below
Conflict of interest: none.
PII: S0360-3016(09)00189-8
doi:10.1016/j.ijrobp.2009.02.002
© 2010 Elsevier Inc. All rights reserved.
Volume 76, Issue 2 , Pages 485-489, 1 February 2010
